Dr Lorente and colleagues [1] report on the interesting association between serum soluble CD40 ligand (sCD40L) levels and mortality in patients with sepsis. Some variables that can infl uence outcome in sepsis were accounted for in their analysis. However, the amount of transfused blood products, which may infl uence levels of sCD40L, was not reported. sCD40L accumulates to biologically relevant levels during storage of blood products [2, 3] , in particular of platelet products. Following transfusion, blood products can induce an infl ammatory reaction -by activating CD40-positive cells -associated with the occurrence of acute lung injury and other potential serious compli cations [3] . Levels of sCD40L were also found to be elevated in patients with lung injury following transfusion [2] . Even more, transfusion itself contributes to mortality in the critically ill [4] , as well as to adverse outcome of sepsis [5] . Taken together, we suggest that blood trans fusion could have potentially infl uenced both serum sCD40L levels and outcome in the study performed by Lorente and colleagues. Th e authors state that modulation of sCD40L levels could represent a therapeutic target. Would it not be more appropriate to question whether sCD40L from (stored) blood products contributed to elevated serum levels in their trial, before embarking on therapeutic interventions? We read with interest the letter by Tuinman and Juff ermans discussing our article recently published in Critical Care [1] showing that circulating levels of sCD40L were associated with mortality in sepsis.
As they stated, the lack of data about blood transfusion is a limitation of our study. In a recently published retrospective cohort study of patients with sepsis by Juff ermans and colleagues [5] , it was found that transfusion of red blood cells or platelets, and the storage time of red blood cells were associated with the development of nosocomial bacterial infection. On the other hand, another study found that all blood components contained higher levels of sCD40L than fresh plasma (with the highest concentration in platelet concentrates) and that circulating sCD40L levels were higher in patients with lung injury following transfusion [2] . In addition, CD40L derived from platelets is a potent activator of neutrophils and mediates sepsis-induced neutrophil recruitment and lung edema in mice [6] .
Despite this limitation, the results of our study (the largest series reporting data about sCD40L in patients with severe sepsis) suggest that sCD40L may be of pathophysiological signifi cance in sepsis due to nonsurvivor patients showing higher sCD40L levels at the moment of diagnosis of severe sepsis than survivor patients. Th us, we think it could be interesting to conduct more research on the role of sCD40L in sepsis, and additionally to study the infl uence of blood transfusion on sCD40L levels and patient prognosis. 
